India, July 18 -- Telomir Pharmaceuticals, Inc. (TELO) reported new positive preclinical results evaluating its lead drug candidate, Telomir-1, in xenograft mice model. Following the news, the company's shares were surging more than 150% in pre-market.
The data showed that Telomir-1 fully reversed STAT1 gene silencing, restoring tumor suppressor in human prostate cancer cells, outperforming chemotherapy drug Paclitaxel or Rapamycin.
Studies are underway to evaluate Telomir-1 across multiple therapeutic areas, including oncology, Wilson's disease, age-related macular degeneration (AMD), autism spectrum disorder, and dysphonia.
Telomir stock had closed at $1.21, up 5.22% on Thursday. It has traded in the range of $1.12 - $8.40 in the last ...